Please type a plus sign (+) inside this box → ⊞

PTO/SB/8A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | | of | 1

Complete if Known	
Application Number	~~09/135,928~~ 09/135,238
Filing Date	August 17, 1998
First Named Inventor	Nolan, Garry P.
Group Art Unit	1632
Examiner Name	R. Shykla, Ph.D.
Attorney Docket Number	A-65635-1/DJB/RMS/DHR

OIPE SEP 10 2001 PATENT & TRADEMARK OFFICE

RECEIVED SEP 18 2001 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	6,114,515		Wu et al.	09/2000	

Duplicate

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1060187

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.	SERIAL NO.
A-65635-1/DJB/RMS	09/135,238
APPLICANT: NOLAN et al.	
FILING DATE August 17, 1998	GROUP ~~1645~~ 1632

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RRS	1	Itoh, et al., "The Polypeptide Encoded by the cDNA for human Cell Surface Antigen Fas Can Mediate Apoptosis," *Cell*, 66:233-243 (1991).
	2	Yonehara, et al., "A Cell-Killing Monoclonal Antibody (ANTI-Fas) to a Cell Surface Antigen Co-Downregulated with the Receptor of Tumor Necrosis Factor," *J. Exp. Med.*, 169:1747-1756 (1989).
	3	Itoh and Nagata, "A Novel Protein Domain Required for Apoptosis," *J. Biol. Chem.*, 268:10932-10937 (1993).
	4	Boldin, et al., "A Novel Protein that Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain," *J. Biol. Chem.*, 270:7795-7798 (1995).
	5	Chinnaiyan, et al., "FADD, a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Initiates Apoptosis," *Cell*, 8145:505-512 (1995).
	6	Chu, et al., "A Fas-associated Protein Factor, FAF1, Potentiates Fas-mediated Apoptosis," *Proc. Natl. Acad. Sci. USA*, 92:11894-11898 (1995).
	7	Okura, et al., "Protection Against Fas/APO-1- and Tumor Necrosis Factor-Mediated Cell Death by a Novel Protein, Sentrin," *J. Immunol.*, 157:4277-4281 (1996).
	8	Sato, et al., "FAP-1: A Protein Tyrosine Phosphatase that Associates with Fas," *Science*, 268:411-415 (1995).
	9	Stanger, et al., "RIP: A Novel Protein Containing a Death Domain that Interacts with Fas/APO-1 (CD95) in Yeast and Causes Cell Death," *Cell*, 8145:513-523 (1995).
RRS	10	Enari, et al., "Involvement of an ICE-like Protease in Fas-Mediated Apoptosis," *Nature*, 375:78-81 (1995).

EXAMINER	RRS	DATE CONSIDERED	10/6/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

616515

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO. A-65635-1/DJB/RMS	SERIAL NO. 09/135,238
APPLICANT: NOLAN et al.	
FILING DATE August 17, 1998	GROUP ~~1643~~ 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RRS	11	Enari, et al., "Sequential Activation of ICE-like and CPP32-like Protease During Fas-Mediated Apoptosis," *Nature*, 380:723-726 (1996).
	12	Tewari et al., "Fas- and Tumor Necrosis Factor-Induced Apoptosis is Inhibited by the Poxvirus *crmA* Gene Product," *J. Biol. Chem*, 270:3255-3260 (1995).
	13	Fernandes-Alnemri, et al., "In Vitro Activation of CPP32 and Mch3 by Mch4, a Novel Human Apoptotic Cysteine Protease Containing Two FADD-Like Domains," *Proc. Natl. Acad Sci. USA*, 93:7464-7469 (1996).
	14	Muzio, et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex," *Cell*, 85:817-827 (1996).
	15	Irmler, et al., "Inhibition of Death Receptor Signals by Cellular FLIP," *Nature*, 388:190-195 (1997).
	16	Srinivasula, et al., "FLAME-1, a Novel FADD-like Anti-Apoptotic Molecule that Regulates Fas/TNFR1-induced Apoptosis," *J. Biol. Chem.*, 272:18542-18545 (1997).
	17	Hu, et al., "I-FLICE, a Novel Inhibitor of Tumor Necrosis Factor Receptor-1- and CD-95-Induced Apoptosis," *J. Biol. Chem.*, 272:17255-17257 (1997).
	18	Cifone, et al., "Apoptotic Signaling Through CD95 (Fas/Apo-1) Activates an Acidic Sphingomyeliuase," *J. Exp. Med.*, 180:1547-1552 (1994).
	19	Tian, et al., "Fas-Activated Serine/Threonine Kinase (FAST) phosphorylate TII During Fas-Mediated Apoptosis," *J. Exp. Med.*, 182:865-874 (1995).
	20	Yang, et al., "Daxx, A Novel Fas-Binding Protein that Activates JNK and Apoptosis," *Cell*, 89:1067-1076 (1997).
	21	Richardson, et al., "Fas Ligation Triggers Apoptosis in Macrophages but not Endothelial Cells," *Eur. J. Immunol.*, 24:2640-2645 (1994).
	22	Arase, et al., "Fas-Mediated Cytotoxicity by Freshly Isolated Natural Killer Cells," *J. Exp. Med.*, 181:1235-1238 (1995).
	23	Berke, "The CTL's Kiss of Death," *Cell*, 81:9-12 (1995).
	24	Montel, et al., "Fas Involvement in Cytotoxicity mediated by Human NK Cells," *Cell Immunol.*, 166:236-246 (1995).
RRS	25	Klas, et al., "Activation Interferes with the APO-1 Pathway in Mature Human T Cells," Int. Immunol., 5(6):625-630 (1993).

EXAMINER	RRS	DATE CONSIDERED	10/6/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

616515

INFORMATION DISCLOSURE CITATION PTO-1449	ATTY. DOCKET NO. A 65035-1/DJB/RMS	SERIAL NO. 09/135,238
	APPLICANT: NOLAN et al.	
	FILING DATE August 17, 1998	GROUP ~~1643~~ 1632

MAY 2 4 1999 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
RRS	26	Owen-Schaub, et al., "DNA Fragmentation and Cell Death is Selectively Triggered in Activated Human Lymphocytes by Fas Antigen Engagement," *Cell Immunol.*, 140:197-205 (1992).
RRS	27	Los et al., "Requirement of an ICE/CED-3 Protease for Fas/APO-1-Mediated Apoptosis," *Nature*, 375:81-83 (1995).

EXAMINER	RRS	DATE CONSIDERED	10/6/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
616515

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.	SERIAL NO.
A-65635-1/DJB/RMS	09/135,238
APPLICANT: Nolan and Hitoshi	
FILING DATE: August 17, 1998	GROUP: 1643

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
RRS	A	0 905 238 A2	03/31/1999	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RRS	1	Hitoshi et al., "Toso, a Cell Surface, Specific Regulator of Fas-Induced Apoptosis in T Cells," *Immunity*, 8:461-471(April 1998).
RRS	2	Rothenberg et al., "Intracellular Combinatorial Chemistry with Peptides in Selection of Caspase-like Inhibitors," *NATO ASI Series, Gene Therapy*, H(105)171-183 (1998).

EXAMINER	RRS	DATE CONSIDERED	10/6/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

085 1449A.FRM (0/95)

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.	SERIAL NO.
A-55635-1/DJB/RMS	09/135,238
APPLICANT: NOLAN et al.	
FILING DATE August 17, 1998	GROUP 1632

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation Yes	Translation No
RRS	A	99/25832	5/1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	RRS	DATE CONSIDERED	10/6/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1004870

Please type a plus sign (+) inside this box → ☐

PTO/SB/8A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known	
Application Number	09/135,328
Filing Date	August 17, 1998
First Named Inventor	Nolan, Gary P.
Group Art Unit	1632
Examiner Name	R. Shykla, Ph.D.
Attorney Docket Number	A-65635-1/DJB/RMS/DHR

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
RRS	1	6,114,515		Wu et al.	09/2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature	RRS	Date Considered	10/7/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.